Rheumatoid Arthritis Foot Surgery 2026 | Podiatrist

Rheumatoid arthritis (RA) produces a specific and predictable pattern of foot and ankle involvement that affects the majority of RA patients over the course of their disease -- understanding this pattern helps patients recognize RA-related foot changes that warrant treatment. The RA foot pathology cascade: RA is a systemic autoimmune disease in which the immune system attacks the synovium (the lining of joints and tendon sheaths); the synovitis (joint inflammation) destroys cartilage, ligaments, and bone; in the foot, this process produces a predictable deformity pattern over time; forefoot involvement (the most common RA foot presentation): the metatarsophalangeal (MTP) joints are almost universally affected in established RA; synovitis in the MTP joints weakens the plantar plate and joint capsule; the toes drift into valgus (toward the outer foot) and the MTP joints sublux (partially dislocate); the metatarsal heads drop plantarward (downward), creating prominent and painful metatarsal heads on the ball of the foot; the toes develop hammertoe and claw toe deformities; characteristic RA forefoot appearance: widened forefoot with lateral deviation of all toes, prominent metatarsal heads on the plantar surface, calluses under each metatarsal head from the dropped metatarsals; hallux valgus (bunion) from RA tends to be more severe than idiopathic hallux valgus and progresses more rapidly; hindfoot involvement: subtalar and talonavicular joint synovitis produces hindfoot pain and progressive valgus deformity (flat foot); the posterior tibial tendon is weakened by adjacent synovitis; the result is a painful, rigid or semi-rigid flatfoot; ankle involvement: tibiotalar joint synovitis produces ankle pain, morning stiffness, and eventually ankle valgus (the ankle tilts outward); end-stage RA ankle arthritis may require ankle replacement or fusion; tendon involvement: the posterior tibial tendon, peroneal tendons, and extensor tendons may develop tenosynovitis (tendon sheath inflammation) causing pain and eventual tendon rupture.

Medical management of the underlying RA (disease-modifying drugs) is the foundation of RA foot care -- controlling systemic inflammation reduces the rate of foot deformity progression; local foot-specific measures address the mechanical consequences of existing deformity. Disease-modifying antirheumatic drugs (DMARDs): methotrexate (the first-line DMARD): reduces systemic RA activity and slows joint destruction throughout the body including the feet; biologic agents (TNF inhibitors: etanercept, adalimumab, infliximab; IL-6 inhibitors: tocilizumab; JAK inhibitors: tofacitinib): significantly reduce RA activity; patients on effective biologic therapy have substantially less foot deformity progression than those managed with non-biologic DMARDs alone; DMARD management is directed by the rheumatologist; the podiatrist coordinates with the rheumatology team for RA patients with significant foot involvement. Footwear for the RA foot: the widened, deformed RA forefoot cannot fit in conventional shoes; extra-depth shoes: 3/8-inch deeper than standard shoes; accommodates hammertoe deformities, orthotics, and the broader RA forefoot; brands: Dr. Comfort, Orthofeet, Propet; custom-moldable footwear: for severe deformities that cannot be accommodated in even extra-depth stock shoes; a shoe fabricated from a mold of the patient's foot; rocker bottom sole: reduces MTP joint loading during push-off, reducing pain over the dropped metatarsal heads. Custom orthotics for the RA foot: custom accommodative orthotics with full-length metatarsal padding distribute weight away from the painful, prominent metatarsal heads; a metatarsal bar across the orthotic proximal to the metatarsal heads is highly effective for RA forefoot pain; total-contact orthotics (distributing weight across the entire plantar surface) reduce focal pressure at any single area. Local treatments: corticosteroid injections into inflamed RA foot joints provide rapid symptom relief during flares; appropriate for acute MTP or ankle flares when the inflammation is localized.

Surgery for RA foot deformity is indicated when conservative management no longer controls pain and function -- RA foot surgery is more complex than non-RA forefoot surgery because the systemic inflammatory process affects tissue quality, healing, and the risk of surgical complications. Forefoot reconstruction (the most commonly performed RA foot surgery): the goal is to eliminate the painful, subluxed MTP joints and realign the toes into a functional position; metatarsal head resection arthroplasty: the heads of the 2nd-5th metatarsals are removed (resected), eliminating the prominence that causes plantar forefoot pain and allowing the toes to realign; simultaneously, the hallux valgus is corrected with a 1st MTP fusion (preferred in RA) or proximal phalangeal excision arthroplasty; this is a comprehensive forefoot reconstruction performed in a single operative session; outcomes: 80-90% patient satisfaction; significant improvement in forefoot pain and walking ability; recovery: 8-12 weeks of protected weight-bearing in a post-operative shoe; standard forefoot surgery (osteotomies) used for non-RA bunions is generally not appropriate in RA because the systemic synovitis affects healing and bone quality; fusion of the 1st MTP joint is preferred to joint-sparing procedures in RA because the inflammatory process will continue to attack a preserved joint surface; hindfoot reconstruction: for progressive RA hindfoot valgus deformity (flat foot collapse); subtalar fusion, talonavicular fusion, or triple arthrodesis (fusion of the subtalar, talonavicular, and calcaneocuboid joints simultaneously) corrects hindfoot alignment; triple arthrodesis is the most comprehensive option for severe hindfoot RA; ankle surgery: RA ankle replacement (total ankle arthroplasty): appropriate for low-demand older RA patients with preserved bone quality; ankle arthrodesis (fusion): more reliable long-term in RA due to the systemic inflammatory process affecting implant longevity.

Rheumatoid arthritis medications have important interactions with the surgical and healing process -- coordination between the rheumatologist and the podiatric surgeon is essential for planning elective foot surgery in RA patients. Methotrexate and healing: methotrexate is the most commonly used DMARD in RA; historically, surgeons withheld methotrexate perioperatively (around the time of surgery) due to concerns about infection and wound healing; current evidence: multiple well-designed studies now show that continuing methotrexate through the perioperative period does NOT increase wound complications or infection risk for elective foot surgery; withholding methotrexate risks a RA flare that impairs surgical planning and recovery; current standard: continue methotrexate through the perioperative period for most elective foot procedures; the surgeon and rheumatologist should discuss this jointly. Biologic agents (TNF inhibitors, IL-6 inhibitors, JAK inhibitors): biologics significantly impair the immune response that defends against surgical site infection; these medications represent a more meaningful perioperative risk than methotrexate; the American College of Rheumatology (ACR) guidelines recommend withholding biologic agents for one dosing interval before elective surgery; examples: adalimumab (biweekly dosing) -- withhold for 2 weeks before surgery; etanercept (weekly or biweekly) -- withhold for 1-2 weeks; tocilizumab -- withhold for 4 weeks; resume the biologic after wound healing is confirmed (typically 2-4 weeks post-op); the risk-benefit decision is individualized -- a patient with well-controlled RA may tolerate withholding the biologic without a flare, while a patient with active, difficult-to-control RA may be at greater risk from a flare than from the biologic perioperatively. Corticosteroids: RA patients who take chronic prednisone are at increased risk for infection and impaired wound healing; stress dosing (increased corticosteroid dose around the time of surgery) may be required for patients on long-term steroids to prevent adrenal insufficiency; the dose and taper are managed by the prescribing rheumatologist.